Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings

Business Wire April 20, 2017

Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome

Business Wire April 17, 2017

Aurinia Pharma Shares Could Be A 2-Bagger From Here

Benzinga.com  April 11, 2017

Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL

Business Wire April 10, 2017

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  April 7, 2017

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  April 7, 2017

Aurinia Announces Development Plans for Voclosporin in Europe and Japan

Business Wire April 6, 2017

Adam Feuerstein Sees Major Price Manipulation In Small-Cap Pharma Stocks

Benzinga.com  April 5, 2017

20 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  March 27, 2017

Watch These 5 Huge Put Purchases In Monday Trade

Benzinga.com  March 27, 2017

Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Business Wire March 27, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  March 22, 2017

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Business Wire March 20, 2017

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  March 20, 2017

Don't Let Offerings Blindside Your Thesis

Benzinga.com  March 19, 2017

Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Business Wire March 16, 2017

6 Tweets Tell The Aurinia Pharma Story

Benzinga.com  March 14, 2017

Mid-Morning Market Update: Markets Open Lower; DSW Earnings Beat Views

Benzinga.com  March 14, 2017

Aurinia Prices US$150.5 Million Public Offering of Common Shares

Business Wire March 14, 2017

Aurinia Announces Public Offering of Common Shares

Business Wire March 13, 2017